Johannes F. van Agthoven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Johannes F. van Agthoven has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Donghai Wen
Nephrology Division, Mass General Brigham, Harvard Medical School, Boston, MA, United States; Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
2 shared publications - Eugene P. Rhee
Division of Nephrology, Department of Medicine, Mass General Brigham, Boston, Massachusetts
2 shared publications - Astrid Weins
Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
1 shared publication - Insa Marie Schmidt
Section of Nephrology, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts
1 shared publication - Ivy A. Rosales
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
1 shared publication - M. Amin Arnaout
Nephrology Division, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
1 shared publication
Latest Publications
- 9 May 2026
- Published by Elsevier in Matrix Biology
- Vol. 146, 102013
Testican-2 (SPOCK2): A multifunctional matricellular regulator
- 9 May 2026
- Published by Elsevier in Matrix Biology
- Vol. 146, 102013
Testican-2 (SPOCK2): A multifunctional matricellular regulator
- 28 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 700-712
Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection
Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.
- 28 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 700-712
Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection
Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.